Prevalence

Complement 3 Glomerulopathy (C3G) Epidemiology Forecast Report 2021-2030 with Focus on United States, Germany, Spain, Italy, France, United Kingdom and Japan - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:44am

This 'Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the disease, historical and forecasted Complement 3 Glomerulopathy (C3G) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Points: 
  • This 'Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the disease, historical and forecasted Complement 3 Glomerulopathy (C3G) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in the seven major markets was found to be 8,456 in 2020.
  • The diagnosed prevalent cases of Complement 3 Glomerulopathy (C3G), in the United States, were found to be 4,112 in 2020.
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Complement 3 Glomerulopathy (C3G) during the forecast period (2021-2030)?

Global Liver Cancer Diagnostics Market (2021 to 2028) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:40am

The "Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Type (Laboratory Tests, Imaging Tests, Endoscopy, Biopsy), by End-use, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Type (Laboratory Tests, Imaging Tests, Endoscopy, Biopsy), by End-use, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global liver cancer diagnostics market size is expected to reach USD 17.4 billion by 2028.
  • The rising prevalence of liver cancer and the introduction of innovative diagnosis products are propelling the market growth.
  • The most common cause of liver cancer is chronic (long-term) infection with Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV).

United States $950+ Mn Continuous Renal Replacement Therapy Markets, 2021-2028 by Product (CRRT System, Disposables, Liquids), & Modality (SCUF, CVVH, CVVHD, CVVHDF) - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:08am

Continuous Renal Replacement Therapy Market 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Continuous Renal Replacement Therapy Market 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. continuous renal replacement therapy market size is expected to reach USD 957.2 million by 2028.
  • It is expected to expand at a CAGR of 6.1% from 2021 to 2028.
  • The Continuous Venovenous Hemodiafiltration (CVVHDF) segment is expected to expand at the highest volume-based CAGR during the forecast period

Global Chemiluminescence Immunoassay Market Report 2021-2028 - Focus on Consumables, Instruments, Software & Services - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:18am

The "Global Chemiluminescence Immunoassay Market Size, Share & Trends Analysis Report by Product (Consumables, Instruments, Software & Services), by Application, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chemiluminescence Immunoassay Market Size, Share & Trends Analysis Report by Product (Consumables, Instruments, Software & Services), by Application, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • Key players in the market are implementing organic and inorganic growth strategies for the development, launch, and distribution of novel CLIA solutions.
  • However, the high setup cost of automated chemiluminescence immunoassay systems is expected to be a major factor hindering the market growth.
  • The emergence of local players in developing markets, such as India and China, is primarily driving the regional market

Antech introduces veterinary medicine's most advanced parasite screening test

Retrieved on: 
Monday, January 17, 2022 - 11:30am

Antech's investment in molecular technology, including 10 testing locations across North America, supports affordable next-day results, making advanced molecular parasite screening practical for routine wellness exams.

Key Points: 
  • Antech's investment in molecular technology, including 10 testing locations across North America, supports affordable next-day results, making advanced molecular parasite screening practical for routine wellness exams.
  • However, today's parasitic infection challenges have outpaced the capabilities of existing screening tests, the most common being the 100-year-old Ova and Parasite (O&P) diagnostic protocol.
  • KeyScreen GI Parasite PCRoffers several novel capabilities, supporting practice efficiency, rapid, cost-effective detection of more disease and a new, higher standard of care for parasite screening.
  • Today, Antech is driving the future of pet health as part of Mars Veterinary Health, a family-owned enterprise focused on veterinary care.

Global Drone Analytics (Power & Utility, Construction & Infrastructure) Market Size, Share & Trends Analysis Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 10:03am

The "Global Drone Analytics Market Size, Share & Trends Analysis Report by End-use (Power & Utility, Construction & Infrastructure), by Application, by Deployment (On-premise, On-demand), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Drone Analytics Market Size, Share & Trends Analysis Report by End-use (Power & Utility, Construction & Infrastructure), by Application, by Deployment (On-premise, On-demand), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • To monetize the promising growth opportunities, leading players are focusing on integrating advanced technologies in their offerings for enhanced performance.
  • Specialized drone analytics solutions play a crucial role in the collection of data as compared to traditional data collecting tools.
  • Construction and infrastructure sectors are embracing drone analytics solutions at a greater pace.

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

Retrieved on: 
Monday, January 17, 2022 - 10:08am

HANGZHOU and SHAOXING, China, Jan. 17, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC22 (Envafolimab), a first-in-class, subcutaneously administered PD-L1 antibody for functional cure of chronic hepatitis B (CHB).

Key Points: 
  • Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.
  • "ASC22 (Envafolimab) U.S. IND approval enables us to initiate U.S. and global clinical trials for CHB functional cure.
  • Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody ASC22 and Pegasys as cornerstone drugs.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

Retrieved on: 
Monday, January 17, 2022 - 9:53am

Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.

Key Points: 
  • Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.
  • "ASC22 (Envafolimab) U.S. IND approval enables us to initiate U.S. and global clinical trials for CHB functional cure.
  • Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody ASC22 and Pegasys as cornerstone drugs.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.

The Carl Kruse Blog Invites Everyone To SETI Chat: Artificial Intelligence, Augmenting Humanity For Good

Retrieved on: 
Saturday, January 15, 2022 - 5:00pm

The SETI Institute has invited two AI experts for a chat to explore the advantages -- and some of the pitfalls -- of deploying AI for the future of society. Alex Lavin and Siddha Ganju, two AI experts and entrepreneurs gather to talk all things AI. The head of the Trillium company, James Paar moderates the talk. The chat hopes to provide an accessible conversation on technologies vital for the future of humanity.

Key Points: 
  • As with many significant human inventions, such as nuclear power, capabilities for good are often accompanied by the potential for doing harm.
  • Carl Kruse, chair of the Berlin Chapter of the Princeton University Alumni Association in Germany, sponsors these SETI Talks.
  • The blog has sponsored the SETI Talk: UAPs Are They Worth Scientific Attention ?
  • Its members were active in the SETIatHome project and follow developments in scientific exploration of space, artificial intelligence and computer technology.

Global DNA Sequencing Market Report 2022: Market to Reach $10.1 Billion by 2026 - Increasing Emphasis on Personalized Medicine Drives Market Growth

Retrieved on: 
Friday, January 14, 2022 - 9:15pm

DUBLIN, Jan. 14, 2022 /PRNewswire/ -- The "DNA Sequencing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 14, 2022 /PRNewswire/ -- The "DNA Sequencing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Global market for DNA Sequencing estimated at US$5.1 Billion in the year 2020, is projected to reach a revised size of US$10.1 Billion by 2026, growing at a CAGR of 11.8% over the analysis period.
  • Growth in the global market is set to be driven by promising opportunities in the fields of biomarkers, cancer, diagnostics, personalized medicine, forensics and reproductive health among others.
  • The increase in genome mapping programs worldwide, rise in partnerships and collaborations, and growing technological developments in DNA sequencing are the other factors promoting growth in the market.